MannKind | MNKD - Assets


MannKind reported $722.62M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Adma Biologics USD 732.48M 48.28M Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Insmed USD 2.23B 123.49M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
MannKind USD 722.62M 9.69M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 888M 67.57M Sep/2026
Novo Nordisk DKK 90.92B 468.3B Jun/2026
Pfizer USD 204.54B 3.41B Sep/2026
Sanofi EUR 130.29B 1.23B Sep/2026
Xencor USD 770.5M 45.54M Sep/2026